三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LABU 三倍做多标普生物-Direxion

休市中 06-12 16:00:00 EDT

178.62

+4.13

+2.37%

盘后178.50

-0.12-0.07%

19:57 EDT

最高185.26	最低175.60	成交量49.21万
今开175.72	昨收174.49	日振幅5.54%
总市值5.49亿	流通市值5.49亿	总股本307.45万
成交额8,894万	换手率16.00%	流通股本307.45万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多标普生物-Direxion","latestPrice":178.62,"timestamp":1781294400000,"preClose":174.49,"halted":0,"volume":492053,"hourTrading":{"tag":"盘后","latestPrice":178.5,"preClose":178.62,"latestTime":"19:57 EDT","volume":4063,"amount":727586.6985,"timestamp":1781308621423,"change":-0.12,"changeRate":-0.000672,"amplitude":0.010021},"delay":0,"changeRate":0.023668978164937793,"floatShares":3074486,"shares":3074486,"eps":0,"marketStatus":"休市中","change":4.13,"latestTime":"06-12 16:00:00 EDT","open":175.72,"high":185.26,"low":175.6,"amount":88937448.0281,"amplitude":0.055361,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":174.49,"sharesOutstanding":3024486,"nav":174.343,"aum":536015061.29,"dividendRate":0.006936,"bidAskSpread":0.00374,"preHourTrading":{"tag":"盘前","latestPrice":174.9,"preClose":174.355,"latestTime":"09:17 EDT","volume":2664,"amount":467611.06752000004,"timestamp":1781270221625,"change":0.545,"changeRate":0.003126,"amplitude":0.038076},"postHourTrading":{"tag":"盘后","latestPrice":178.5,"preClose":178.62,"latestTime":"19:57 EDT","volume":4063,"amount":727586.6985,"timestamp":1781308621423,"change":-0.12,"changeRate":-0.000672,"amplitude":0.010021},"volumeRatio":0.7086886236515672,"impliedVol":0.9324,"impliedVolPercentile":0.749},"requestUrl":"/m/hq/s/LABU","defaultTab":"news","newsList":[{"id":"2642026565","title":"迈威生物(688062.SH)：注射用6MW5311临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2642026565","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642026565?lang=zh_cn&edition=full","pubTime":"2026-06-12 16:25","pubTimestamp":1781252747,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物(688062.SH)发布公告，近日，公司收到美国食品药品监督管理局(FDA)签发的《临床研究继续进行通知书》，注射用6MW5311用于血液瘤(急性髓系白血病(AML)、慢性粒单核细胞白血病(CMML)以及多发性骨髓瘤(MM))适应症的临床试验申请正式获得FDA许可。此外，6MW5311临床试验申请已获得国家药品监督管理局受理。6MW5311为全球首款获批开展临床试验的靶向LILRB4/CD3的TCE创新药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","BK0239","BK4588","688062","BK1161","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167341696","title":"医疗健康板块市场动态综述","url":"https://stock-news.laohu8.com/highlight/detail?id=1167341696","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167341696?lang=zh_cn&edition=full","pubTime":"2026-06-12 04:53","pubTimestamp":1781211222,"startTime":"0","endTime":"0","summary":"在近期举行的美国糖尿病协会会议上，诺和诺德确认，口服Wegovy自推出以来已开具300万份处方。“整整82%的处方医生是体重管理领域的新手，我们认为这表明口服疗法正在帮助扩大市场。”会议还重点介绍了几项新研究，这些研究间接加强了对GLP-1疗法在体重管理中应用的支持，这可能有助于在保险公司和监管机构此前限制较多的市场（如瑞典）提高治疗可及性。股价下跌1%，至280.20丹麦克朗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LABU","BK4581","XLV","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133908394","title":"医疗保健板块市场动态综述","url":"https://stock-news.laohu8.com/highlight/detail?id=1133908394","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133908394?lang=zh_cn&edition=full","pubTime":"2026-06-12 00:23","pubTimestamp":1781194997,"startTime":"0","endTime":"0","summary":"最新一期医疗保健板块市场动态聚焦于行业内的关键讨论。SB1 Markets认为，该公司目前在口服肥胖治疗领域拥有明显优势，而礼来则在注射疗法领域占据相应领先地位。在近期举行的美国糖尿病协会会议上，诺和诺德确认，自上市以来，口服Wegovy已开出300万张处方。SB1 Markets指出：“高达82%的处方医生是体重管理领域的新手，在我们看来，这表明口服疗法正在帮助扩大市场。”诺和诺德股价下跌1%，至280.20丹麦克朗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4581","XLV","LABU","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642284048","title":"FDA时隔25年批准新型防晒成分，提升UVA/UVB防护水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2642284048","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642284048?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:48","pubTimestamp":1781182080,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局本周正式批准将bemotrizinol列入非处方防晒霜的许可活性成分清单。这是自1990年代末以来，美国首次批准全新的防晒过滤成分，结束了长达二十余年的创新停滞。与现有的一些防晒成分相比，Bemotrizinol具有更高的光稳定性，即在阳光下不易分解，这意味着其防护效果持续时间更长。　　皮肤癌基金会及多位皮肤科专家对这一批准表示欢迎，认为这是皮肤癌预防领域的重要公共卫生进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-11/doc-iniazyem3926943.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191053663","title":"医疗保健板块热点速递：市场动态聚焦","url":"https://stock-news.laohu8.com/highlight/detail?id=1191053663","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191053663?lang=zh_cn&edition=full","pubTime":"2026-06-11 16:23","pubTimestamp":1781166219,"startTime":"0","endTime":"0","summary":"最新一期聚焦医疗保健板块的市场动态速递。阿斯利康股价开盘基本持平。该公司股价下跌2.1%，至366.00印尼盾。欧洲斯托克600医疗保健指数上涨0.5%。瑞银分析师在一份研究报告中表示，葛兰素史克拟议收购Nuvalent的交易对这家英国制药商而言是绝佳匹配，并为其未来推出肺癌药物ris-rez奠定了基础。瑞银表示，这两款Nuvalent药物通过改善现有疗法的疗效和耐受性，合计有潜力实现37.5亿美元的峰值销售额。葛兰素史克股价大体持平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XBI","BK4585","LABU","XLV","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139258159","title":"医疗健康板块综述：市场热议聚焦","url":"https://stock-news.laohu8.com/highlight/detail?id=1139258159","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139258159?lang=zh_cn&edition=full","pubTime":"2026-06-11 04:55","pubTimestamp":1781124902,"startTime":"0","endTime":"0","summary":"欧洲大型制药企业在今年下半年将迎来繁忙日程，数项关键事件有望助其构建积极前景并赢得投资者青睐。据美国银行分析师指出，诺华和阿斯利康在临床试验结果公布方面日程最为密集。此外，分析师补充道，葛兰素史克和赛诺菲新近任命的首席执行官预计将在第二季度财报发布之际，就其战略规划提供最新进展。对于诺和诺德，美国银行表示，市场关注焦点仍将集中在其肥胖与糖尿病产品的处方趋势上。斯托克欧洲600医疗保健指数目前上涨0.5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4585","XLV","XBI","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174033257","title":"医疗健康板块综述：市场动态聚焦制药巨头与手套商","url":"https://stock-news.laohu8.com/highlight/detail?id=1174033257","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174033257?lang=zh_cn&edition=full","pubTime":"2026-06-11 00:23","pubTimestamp":1781108609,"startTime":"0","endTime":"0","summary":"欧洲大型制药公司下半年日程紧凑，一系列关键事件有望助其构建积极前景并赢得投资者青睐。他们补充道，葛兰素史克和赛诺菲新近任命的首席执行官预计将在发布第二季度财报时，同步更新其战略规划。对于诺和诺德，分析师认为其焦点仍将集中在肥胖与糖尿病产品的处方趋势上。罗氏的下半年则相对平静，但其新型乳腺癌药物giredestrant的上市将成为关键。欧洲斯托克600医疗健康指数当前上涨0.5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4581","BK4585","BK4588","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442824","title":"宝济药业-B：皮下输注用头孢曲松钠BJ007临床试验获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442824","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642442824?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:05","pubTimestamp":1781089500,"startTime":"0","endTime":"0","summary":"6月10日，宝济药业-B（02659）发布公告，公司于2026年5月27日获得美国食品药品监督管理局(FDA)批准，开展皮下输注用头孢曲松钠BJ007的临床试验。BJ007是用于治疗细菌感染的皮下给药头孢曲松钠产品，全球尚无皮下给药头孢曲松钠获得批准，BJ007为该类别首款进入临床阶段的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606103766846240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LABU","BK4585","02659","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642468104","title":"港股异动 | 石药集团(01093)盘中涨超4% 司美格鲁肽长效注射液(SYH9017)获FDA批准临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2642468104","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642468104?lang=zh_cn&edition=full","pubTime":"2026-06-10 15:50","pubTimestamp":1781077840,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，石药集团盘中涨超4%，截至发稿，涨3.57%，报7.25港元，成交额7.14亿港元。消息面上，石药集团公告，集团开发的GLP-1受体激动剂司美格鲁肽长效注射液已获美国食品药品监督管理局批准，可在美国开展临床试验。据悉，该产品是本集团在GLP-1领域布局的首个每月给药一次的长效制剂。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YR35.GBP","LU0315179316.USD","BK4585","LU0501845795.SGD","BK1515","01093","LU1152091754.HKD","LU1008478684.HKD","VXUS","LU0326950275.SGD","LU1226287875.USD","LU1807302812.USD","IE00B031HY20.USD","LU1813983027.USD","LU0314109678.HKD","LU0880133367.SGD","BK1521","IE00B5MMRT66.SGD","IE0008368742.USD","LU1226287792.SGD","LU0072913022.USD","LU1328277881.USD","LU1993786604.SGD","LU1226288170.HKD","IE00BZ08YT58.USD","LABU","LU1226288253.USD","LU1960683339.HKD","LU1951186391.HKD","HK0000165453.HKD","BK4588","IE00B543WZ88.USD","IE00BZ08YS42.EUR","SG9999004220.SGD","BK1191","IE0008369823.USD","LU2039709279.SGD","LU1152091168.USD","LU1226287529.USD","LU0140636845.USD","LU0067412154.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156980149","title":"医疗健康板块热点速递：市场动态一览","url":"https://stock-news.laohu8.com/highlight/detail?id=1156980149","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156980149?lang=zh_cn&edition=full","pubTime":"2026-06-10 04:53","pubTimestamp":1781038402,"startTime":"0","endTime":"0","summary":"最新一期医疗健康板块市场动态速递。此次上调规模表明，市场对Apotex及其股东出售股票的需求强劲，足以支持其超越最初的计划。葛兰素史克股价下跌1.3%。瑞银分析师维持对该股的买入评级，但在给客户的报告中警告称，市场普遍预测CSL血浆制品业务利润率将扩大90个基点，这一预期过高。他们预计，每位捐赠者采集量增长10%将带来改善，并称这将有助于抵消价格和竞争压力。股价上涨0.6%至98.49澳元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4539","NUVL","BK4585","BK4581","XLV","BK4139","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642965614","title":"Medline因FDA违规警告面临证券欺诈调查","url":"https://stock-news.laohu8.com/highlight/detail?id=2642965614","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642965614?lang=zh_cn&edition=full","pubTime":"2026-06-09 23:02","pubTimestamp":1781017320,"startTime":"0","endTime":"0","summary":"医疗器械供应商Medline Industries近日陷入监管危机。美国食品药品监督管理局于5月28日向该公司发出警告信，指出其位于伊利诺伊州的工厂存在“严重违反成品药现行良好生产规范规定”的行为。这是FDA在两个月内第二次向该公司发出警告信。　　Medline需要在15个工作日内向FDA回应，详细说明所采取的纠正行动，否则可能面临暂停签发出口证书等监管措施。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-09/doc-iniavshh6272582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161027","BK4585","BK4198","BK4588","LABU","MDLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152725195","title":"医疗保健板块市场动态聚焦","url":"https://stock-news.laohu8.com/highlight/detail?id=1152725195","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152725195?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:23","pubTimestamp":1780993391,"startTime":"0","endTime":"0","summary":"科技股反弹抵消了医疗保健和软件板块的跌幅，泛欧斯托克600指数表现持平。伦敦富时100指数下跌0.3%，因医疗保健股走低，其中葛兰素史克在同意收购生物制药公司Nuvalent后股价下跌2.5%。软件公司励讯集团和赛捷集团均下跌约2%。银行和奢侈品集团的温和上涨助力法国CAC 40指数上扬0.3%。德国DAX指数微升0.1%，得益于半导体公司英飞凌科技股价上涨2.7%。意大利银行股延续涨势，推动米兰富时MIB指数上涨0.7%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","XBI","BK4588","XLV","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642863452","title":"石药GLP-1月制剂闯关FDA：加速走出低价仿制红海，国产减肥药卷到新维度","url":"https://stock-news.laohu8.com/highlight/detail?id=2642863452","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642863452?lang=zh_cn&edition=full","pubTime":"2026-06-09 14:13","pubTimestamp":1780985622,"startTime":"0","endTime":"0","summary":"在仿制端，司美格鲁肽类似药的大规模放量将迅速拉低整体GLP-1针剂的价格门槛，惠及广大患者的同时加速尾部药企出清。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1780984647666134242","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IE0008369823.USD","LU0880133367.SGD","LU1951186391.HKD","LU0315179316.USD","BK4588","LU1993786604.SGD","LU0501845795.SGD","01093","BK4590","IE00BZ08YS42.EUR","LU1226287529.USD","BK4144","LU1328277881.USD","LU0072913022.USD","BK1521","BK1515","LU1008478684.HKD","LU0326950275.SGD","LU1813983027.USD","IE00BZ08YR35.GBP","LABU","IE00B031HY20.USD","LU1226287792.SGD","SG9999004220.SGD","LU0314109678.HKD","BK4585","IE0008368742.USD","LU2039709279.SGD","LU0067412154.USD","LU0140636845.USD","LU1226287875.USD","LU1226288253.USD","HK0000165453.HKD","LU1152091168.USD","LU1960683339.HKD","BK1191","LU1226288170.HKD","LU1152091754.HKD","IE00BZ08YT58.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","GLP","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641045171","title":"百利天恒(688506.SH)：BL-M14D1(DLL3ADC)联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2641045171","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641045171?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:36","pubTimestamp":1780904174,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，公司的全资子公司 SystImmune,Inc.近日收到美国食品药品监督管理局的通知， BL-M14D1联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请已获得FDA许可。BL-M14D1与iza-bren 共享同一小分子技术平台，公司拥有其完整的全球权益。本次BL-M14D1的III期临床研究获得FDA的IND许可，将进一步推进公司业务和产品国际化布局的进程，对公司近期业绩不会产生重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451325.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["91194","BK4585","LU0757428866.USD","III","LABU","688506","BL","BK4134","BK4023","BK4588","BK0239","02615","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149997054","title":"医疗健康板块市场动态聚焦","url":"https://stock-news.laohu8.com/highlight/detail?id=1149997054","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149997054?lang=zh_cn&edition=full","pubTime":"2026-06-06 00:26","pubTimestamp":1780676796,"startTime":"0","endTime":"0","summary":"最新一期医疗健康板块市场动态发布。美东时间凌晨2点06分 - 伯恩斯坦分析师在一份研究报告中指出，阿斯利康在其核心肿瘤业务之外发布的管线药物数据前景乐观，但市场似乎低估了其价值。Bell Potter表示，这一差距反映了过去几个月，在市场等待EBR启动融资期间，其股价的急剧下跌。EBR Systems股价下跌11%，报0.39澳元。（本文已进行更正，以反映EBR Systems计划以每股0.38澳元筹集1.08亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4581","BK4588","LABU","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641164638","title":"Alvotech再次向FDA提交强生Simponi和再生元Eylea生物类似药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2641164638","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641164638?lang=zh_cn&edition=full","pubTime":"2026-06-05 03:16","pubTimestamp":1780600560,"startTime":"0","endTime":"0","summary":"冰岛生物制药公司Alvotech周四宣布，已再次向美国食品药品监督管理局提交两款生物类似药的生物制剂许可申请，分别针对强生的Simponi和再生元的Eylea。此次提交是与合作伙伴Teva共同推进的，标志着两家公司在拓展美国生物类似药市场方面迈出关键一步。AVT05是强生旗下Simponi及其静脉注射剂型Simponi Aria的生物类似药，该药属于肿瘤坏死因子阻滞剂，用于治疗类风湿关节炎、银屑病关节炎、强直性脊柱炎、溃疡性结肠炎等多种慢性炎症性疾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-05/doc-iniahtfh8923892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2417539215.USD","LU2213496289.HKD","IE000F7OJYX1.SGD","LU1551013425.SGD","IE00BLSP4452.SGD","BK4139","IE000BZT7R73.USD","IE00B3PB1722.GBP","LU1585245621.USD","LU1074936037.SGD","IE00B19Z3581.USD","IE00B3T34201.USD","LU1066051225.USD","BK4588","LU1121112475.USD","LU1629891620.HKD","IE00BN8TJ469.HKD","LU2430703178.SGD","LU0882574055.USD","IE00B1BXHZ80.USD","LU0545562505.USD","LU1280957306.USD","IE00BLSP4239.USD","LU2112291526.USD","LU1244550577.SGD","BK4592","LU1894683348.USD","LU0203345920.USD","IE00BJT1NW94.SGD","ALVO","SG9999001176.USD","LU2133065610.SGD","IE000SO60NU8.SGD","BK4007","BK4504","LU2750360641.GBP","SG9999002232.USD","IE00BDGV0183.EUR","LU1261432733.SGD","LABU","LU0432979614.USD","LU0964807845.USD","LU1032466523.USD","JNJ","LU0689626769.HKD","LU0053666078.USD","LU0114720955.EUR","IPOS","LU0683600562.USD","LU1228905037.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641161560","title":"欧洲股市反弹 医疗保健板块领涨 渣打和汇丰等英国银行股下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2641161560","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641161560?lang=zh_cn&edition=full","pubTime":"2026-06-05 01:42","pubTimestamp":1780594920,"startTime":"0","endTime":"0","summary":"欧洲股市周四反弹，医疗保健股上涨，Abivax SA和Zealand Pharma A/S涨幅居前。　　斯托克欧洲600指数收盘上涨0.5%，摆脱早盘跌势。医疗保健、金融服务和零售板块领涨，矿业股和电信股表现最差。　　Abivax大涨18%，此前该股因一项关键临床试验中的癌症病例而暴跌。　　欧洲股市今年以来上涨逾5%，但仍落后于美国和亚洲市场的涨势，后两者对AI主题的敞口更大。这导致瑞银集团的一篮子AI赢家股票下跌1.6%，不过该篮子今年以来仍上涨逾40%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-05/doc-iniahnxk9041101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0128525689.USD","BK1572","BK4207","BK1601","FEZ","BK4588","BK4581","LU2236285917.USD","LU0149534421.HKD","XBI","HSBC","LU0211977185.USD","IEUR","XLV","LU0211326839.USD","02888","LU0496365809.HKD","LABU","HSBH","SG9999000327.SGD","FLEE","03143","LU0607220059.USD","LU0310800965.SGD","BK4550","VGK","LU0211326755.USD","LU0052756011.USD","LU0976567544.SGD","SPEU","EPV","SG9999001689.USD","LU1267930227.SGD","BK4521","VEA","BK4585","BK4504","BK4534","BK1619","VHT","BK1231","EURL","IEV","IEFA","STAN.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120703317","title":"医疗保健板块市场动态聚焦","url":"https://stock-news.laohu8.com/highlight/detail?id=1120703317","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120703317?lang=zh_cn&edition=full","pubTime":"2026-06-04 00:22","pubTimestamp":1780503772,"startTime":"0","endTime":"0","summary":"0548 ET - AJ Bell的Russ Mould指出，诺和诺德在阿联酋推出其口服减肥药Wegovy是一个重要的里程碑，这标志着该公司首次在美国以外地区推出其肥胖治疗药物的口服版本。Mould称，这一点在美国市场已得到印证，口服剂型于今年初推出后，需求一直很健康。诺和诺德的主要竞争对手礼来公司已于四月宣布在阿联酋推出其自身的口服减肥药。诺和诺德股价上涨0.1%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XLV","BK4585","LABU","XBI","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640004908","title":"云南白药(000538.SZ)：INB301注射液获美国FDA新药临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2640004908","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640004908?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:57","pubTimestamp":1780480643,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云南白药(000538.SZ)发布公告，公司于近日收到美国食品药品监督管理局(简称“美国FDA”)的通知，由公司申报的INB301注射液新药临床试验申请(简称“IND”)已获得美国FDA许可，同意开展临床试验，拟开发适应症为肿瘤恶病质。该药品为公司研发的首个治疗用生物创新药，拟用于治疗肿瘤恶病质。肿瘤恶病质是一种由恶性肿瘤引发的复杂代谢紊乱综合征，以持续性骨骼肌消耗为特征，常规营养支持难以逆转。截至目前，已获得中美两国临床试验许可，累计已投入研发费用约人民币5066.5万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK0188","BK0028","LU1960683339.HKD","LABU","BK0196","BK4585","BK0239","BK0187","LU1993786604.SGD","LU1807302812.USD","BK0012","000538","BK0175","BK0164"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196937471","title":"医疗健康板块市场动态聚焦","url":"https://stock-news.laohu8.com/highlight/detail?id=1196937471","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196937471?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:26","pubTimestamp":1780475203,"startTime":"0","endTime":"0","summary":"最新一期聚焦医疗健康板块的市场对话。他表示，明年公司员工将可以免费使用GLP-1药物，因为他相信这将有助于降低公司的整体医疗成本。分析师表示，负责监督和有权管辖跨地区诉讼的法官小组已将集体诉讼移交至北加州联邦法院，由法官Vince Chhabria审理。该法官在最近的听证会上对该和解方案持负面看法，并在2020年驳回了拜耳解决Roundup诉讼的尝试。拜耳股价下跌5%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","XLV","LABU","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.1146},{"period":"1month","weight":-0.0814},{"period":"3month","weight":0.2},{"period":"6month","weight":0.0838},{"period":"1year","weight":1.9504},{"period":"ytd","weight":0.1206}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.020883},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.009536},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.135885},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.001739},{"month":5,"riseRate":0.545455,"avgChangeRate":0.013816},{"month":6,"riseRate":0.666667,"avgChangeRate":0.110175},{"month":7,"riseRate":0.636364,"avgChangeRate":0.054287},{"month":8,"riseRate":0.636364,"avgChangeRate":-0.004065},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.0652},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.047038},{"month":11,"riseRate":0.818182,"avgChangeRate":0.199161},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.032237}],"exchange":"ARCA","name":"三倍做多标普生物-Direxion","nameEN":"Direxion Daily S&P Biotech Bull 3x Shares"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三倍做多标普生物-Direxion(LABU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三倍做多标普生物-Direxion,LABU,三倍做多标普生物-Direxion股票,三倍做多标普生物-Direxion股票老虎,三倍做多标普生物-Direxion股票老虎国际,三倍做多标普生物-Direxion行情,三倍做多标普生物-Direxion股票行情,三倍做多标普生物-Direxion股价,三倍做多标普生物-Direxion股市,三倍做多标普生物-Direxion股票价格,三倍做多标普生物-Direxion股票交易,三倍做多标普生物-Direxion股票购买,三倍做多标普生物-Direxion股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三倍做多标普生物-Direxion(LABU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}